Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) – Pipeline Review, H2 2016’, provides in depth analysis on Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1)

The report reviews Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AB Science SA

Advenchen Laboratories, LLC

Amgen Inc.

ArQule, Inc.

Ascendis Pharma A/S

Astellas Pharma Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Bayer AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

CASI Pharmaceuticals Inc.

Celon Pharma Sp. z o.o.

Debiopharm International SA

Eddingpharm

Eisai Co., Ltd.

Eli Lilly and Company

Hutchison MediPharma Limited

Incyte Corporation

Johnson & Johnson

Les Laboratoires Servier SAS

Merck KGaA

Novartis AG

Principia Biopharma Inc.

Vichem Chemie Research Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC

2.7.10.1) Overview 10

Therapeutics Development 11

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC

2.7.10.1) - Products under Development by Stage of Development 11

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC

2.7.10.1) - Products under Development by Therapy Area 12

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC

2.7.10.1) - Products under Development by Indication 13

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC

2.7.10.1) - Pipeline Products Glance 16

Late Stage Products 16

Early Stage Products 17

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC

2.7.10.1) - Products under Development by Companies 18

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC

2.7.10.1) - Products under Development by Universities/Institutes 30

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC

2.7.10.1) - Therapeutics Assessment 32

Assessment by Monotherapy/Combination Products 32

Assessment by Mechanism of Action 33

Assessment by Route of Administration 35

Assessment by Molecule Type 37

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC

2.7.10.1) - Companies Involved in Therapeutics Development 39

AB Science SA 39

Advenchen Laboratories, LLC 41

Amgen Inc. 42

ArQule, Inc. 43

Ascendis Pharma A/S 44

Astellas Pharma Inc. 45

AstraZeneca Plc 46

AVEO Pharmaceuticals, Inc. 47

Bayer AG 48

Boehringer Ingelheim GmbH 49

Bristol-Myers Squibb Company 50

CASI Pharmaceuticals Inc. 51

Celon Pharma Sp. z o.o. 52

Debiopharm International SA 53

Eddingpharm 54

Eisai Co., Ltd. 55

Eli Lilly and Company 57

Hutchison MediPharma Limited 58

Incyte Corporation 59

Johnson & Johnson 60

Les Laboratoires Servier SAS 61

Merck KGaA 62

Novartis AG 63

Principia Biopharma Inc. 64

Vichem Chemie Research Ltd. 65

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC

2.7.10.1) - Drug Profiles 66

ARQ-087 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

ASP-5878 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

AV-370 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

AZD-4547 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

B-701 - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

BAY-1163877 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

BMS-986036 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

CPL-043 - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

Debio-1347 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

E-7090 - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

EDP-317 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

ENMD-2076 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

erdafitinib - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

HMPL-453 - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

INCB-54828 - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

infigratinib - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

lenvatinib mesylate - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

lucitanib - Drug Profile 104

Product Description 104

Mechanism Of Action 104

R&D Progress 104

LY-2874455 - Drug Profile 107

Product Description 107

Mechanism Of Action 107

R&D Progress 107

masitinib - Drug Profile 108

Product Description 108

Mechanism Of Action 108

R&D Progress 108

nintedanib - Drug Profile 121

Product Description 121

Mechanism Of Action 121

R&D Progress 121

pazopanib hydrochloride - Drug Profile 130

Product Description 130

Mechanism Of Action 130

R&D Progress 130

pazopanib hydrochloride + pembrolizumab - Drug Profile 137

Product Description 137

Mechanism Of Action 137

R&D Progress 137

PRN-1371 - Drug Profile 138

Product Description 138

Mechanism Of Action 138

R&D Progress 138

Recombinant Peptide to Antagonize FGFR3 for Achondroplasia - Drug Profile 139

Product Description 139

Mechanism Of Action 139

R&D Progress 139

Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile 140

Product Description 140

Mechanism Of Action 140

R&D Progress 140

Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile 141

Product Description 141

Mechanism Of Action 141

R&D Progress 141

S-49076 - Drug Profile 142

Product Description 142

Mechanism Of Action 142

R&D Progress 142

Small Molecules to Antagonize Pan FGFR for Oncology - Drug Profile 143

Product Description 143

Mechanism Of Action 143

R&D Progress 143

sprifermin - Drug Profile 144

Product Description 144

Mechanism Of Action 144

R&D Progress 144

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC

2.7.10.1) - Dormant Projects 146

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC

2.7.10.1) - Discontinued Products 151

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC

2.7.10.1) - Featured News & Press Releases 153

Oct 26, 2016: Eisais LENVIMA (lenvatinib) Nominated for Galien Foundations Best Pharmaceutical Product 153

Oct 24, 2016: Efficacy of Ofev (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST 153

Oct 12, 2016: Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016 154

Oct 09, 2016: ESMO 2016: Lenvatinib Shows Promising Activity in Patients with RET-Positive Adenocarcinoma of the Lung 156

Oct 09, 2016: People with an Advanced Form of Thyroid Cancer Now Able to Benefit From Lenvima (lenvatinib) in Scotland 157

Oct 09, 2016: Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 159

Oct 08, 2016: Phase I study of novel anti-cancer drug uses tumor mRNA expression to identify responders 159

Oct 03, 2016: AB Science has been invited at four international meetings to present new preclinical data showing neuroprotective effect of masitinib in amyotrophic lateral sclerosis (ALS) 160

Sep 30, 2016: Eisai To Initiate Phase III Clinical Study Of Anticancer Agent Lenvatinib As Potential First-Line Therapy For Advanced Renal Cell Carcinoma 162

Sep 29, 2016: Eisai To Present Latest Data On Lenvatinib At ESMO Congress 2016 163

Sep 29, 2016: AB Science Announces the Filing of Masitinib in the Treatment of Amyotrophic Lateral Sclerosis (ALS) to the European Medicines Agency 164

Sep 28, 2016: Bayer presents New Data on BAY 1163877 at ESMO 2016 Congress 165

Sep 21, 2016: Eisai to Present Updates on Lenvatinib in Two Types of Thyroid Cancer at 86th Annual Meeting of the American Thyroid Association 165

Sep 15, 2016: Eisai Receives License For New Indication For Anticancer Agent Kisplyx (Lenvatinib Mesylate) For Treatment Of Advanced Renal Cell Carcinoma 166

Sep 15, 2016: ArQule Announces Publication of Manuscript Highlighting Preclinical Activity of FGFR Inhibitor, ARQ 087, in Peer Reviewed Journal 167

Appendix 168

Methodology 168

Coverage 168

Secondary Research 168

Primary Research 168

Expert Panel Validation 168

Contact Us 168

Disclaimer 169

List of Tables

List of Tables

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Indication, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Number of Products under Development by Companies, H2 2016 18

Number of Products under Development by Companies, H2 2016 (Contd..1) 19

Products under Development by Companies, H2 2016 20

Products under Development by Companies, H2 2016 (Contd..1) 21

Products under Development by Companies, H2 2016 (Contd..2) 22

Products under Development by Companies, H2 2016 (Contd..3) 23

Products under Development by Companies, H2 2016 (Contd..4) 24

Products under Development by Companies, H2 2016 (Contd..5) 25

Products under Development by Companies, H2 2016 (Contd..6) 26

Products under Development by Companies, H2 2016 (Contd..7) 27

Products under Development by Companies, H2 2016 (Contd..8) 28

Products under Development by Companies, H2 2016 (Contd..9) 29

Number of Products under Investigation by Universities/Institutes, H2 2016 30

Products under Investigation by Universities/Institutes, H2 2016 31

Assessment by Monotherapy/Combination Products, H2 2016 32

Number of Products by Stage and Mechanism of Action, H2 2016 34

Number of Products by Stage and Route of Administration, H2 2016 36

Number of Products by Stage and Molecule Type, H2 2016 38

Pipeline by AB Science SA, H2 2016 39

Pipeline by Advenchen Laboratories, LLC, H2 2016 41

Pipeline by Amgen Inc., H2 2016 42

Pipeline by ArQule, Inc., H2 2016 43

Pipeline by Ascendis Pharma A/S, H2 2016 44

Pipeline by Astellas Pharma Inc., H2 2016 45

Pipeline by AstraZeneca Plc, H2 2016 46

Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 47

Pipeline by Bayer AG, H2 2016 48

Pipeline by Boehringer Ingelheim GmbH, H2 2016 49

Pipeline by Bristol-Myers Squibb Company, H2 2016 50

Pipeline by CASI Pharmaceuticals Inc., H2 2016 51

Pipeline by Celon Pharma Sp. z o.o., H2 2016 52

Pipeline by Debiopharm International SA, H2 2016 53

Pipeline by Eddingpharm, H2 2016 54

Pipeline by Eisai Co., Ltd., H2 2016 55

Pipeline by Eli Lilly and Company, H2 2016 57

Pipeline by Hutchison MediPharma Limited, H2 2016 58

Pipeline by Incyte Corporation, H2 2016 59

Pipeline by Johnson & Johnson, H2 2016 60

Pipeline by Les Laboratoires Servier SAS, H2 2016 61

Pipeline by Merck KGaA, H2 2016 62

Pipeline by Novartis AG, H2 2016 63

Pipeline by Principia Biopharma Inc., H2 2016 64

Pipeline by Vichem Chemie Research Ltd., H2 2016 65

Dormant Projects, H2 2016 146

Dormant Projects (Contd..1), H2 2016 147

Dormant Projects (Contd..2), H2 2016 148

Dormant Projects (Contd..3), H2 2016 149

Dormant Projects (Contd..4), H2 2016 150

Discontinued Products, H2 2016 151

Discontinued Products (Contd..1), H2 2016 152

List of Figures

List of Figures

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Top 10 Indication, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy/Combination Products, H2 2016 32

Number of Products by Mechanism of Actions, H2 2016 33

Number of Products by Stage and Mechanism of Actions, H2 2016 33

Number of Products by Routes of Administration, H2 2016 35

Number of Products by Stage and Routes of Administration, H2 2016 35

Number of Products by Molecule Types, H2 2016 37

Number of Products by Stage and Molecule Type, H2 2016 37

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared